Latest Insider Transactions at Silverback Therapeutics, Inc. (SBTX)
This section provides a real-time view of insider transactions for Silverback Therapeutics, Inc. (SBTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Silverback Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Silverback Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 06
2023
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
33,510
+12.08%
|
$33,510
$1.27 P/Share
|
|
Jul 05
2023
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
31,112
-12.89%
|
$186,672
$6.41 P/Share
|
|
Jul 05
2023
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
31,112
+11.41%
|
$31,112
$1.27 P/Share
|
|
Jul 03
2023
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
26,520
-11.2%
|
$159,120
$6.72 P/Share
|
|
Jul 03
2023
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
26,520
+10.07%
|
$26,520
$1.27 P/Share
|
|
Jun 02
2023
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
26,941
-11.35%
|
$161,646
$6.95 P/Share
|
|
Jun 02
2023
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
26,941
+10.2%
|
$26,941
$1.27 P/Share
|
|
Jun 01
2023
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
73,059
-25.78%
|
$438,354
$6.8 P/Share
|
|
Jun 01
2023
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
73,059
+20.5%
|
$73,059
$1.27 P/Share
|
|
May 17
2023
|
Richard E Lowenthal PRESIDENT AND CEO |
BUY
Bona fide gift
|
Indirect |
2,100,000
+41.67%
|
-
|
|
May 17
2023
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Bona fide gift
|
Indirect |
1,050,000
-24.27%
|
-
|
|
May 17
2023
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Bona fide gift
|
Direct |
1,050,000
-20.28%
|
-
|
|
May 17
2023
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
BUY
Bona fide gift
|
Indirect |
2,100,000
+41.67%
|
-
|
|
May 17
2023
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
SELL
Bona fide gift
|
Indirect |
1,050,000
-20.28%
|
-
|
|
May 17
2023
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
SELL
Bona fide gift
|
Direct |
1,050,000
-24.27%
|
-
|
|
May 09
2023
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
42,900
-16.94%
|
$214,500
$5.31 P/Share
|
|
May 09
2023
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
42,900
+14.49%
|
$42,900
$1.27 P/Share
|
|
May 08
2023
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
57,100
-21.35%
|
$342,600
$6.16 P/Share
|
|
May 08
2023
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
57,100
+17.59%
|
$57,100
$1.27 P/Share
|
|
Nov 29
2022
|
Kathleen D. Scott Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
8,250
+50.0%
|
$49,500
$6.24 P/Share
|
|
Nov 09
2022
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
43,896
-17.27%
|
$175,584
$4.58 P/Share
|
|
Nov 08
2022
|
Rajeev Dadoo |
BUY
Grant, award, or other acquisition
|
Indirect |
3,009,677
+50.0%
|
-
|
|
Nov 08
2022
|
Michael Kelly |
BUY
Grant, award, or other acquisition
|
Indirect |
83,225
+50.0%
|
-
|
|
Nov 08
2022
|
Richard E Lowenthal PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
7,872,554
+50.0%
|
-
|
|
Nov 08
2022
|
Richard E Lowenthal PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
5,176,822
+50.0%
|
-
|
|
Nov 08
2022
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Indirect |
7,872,554
+50.0%
|
-
|
|
Nov 08
2022
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,326,854
+50.0%
|
-
|
|
Nov 08
2022
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
3,009,678
+50.0%
|
-
|
|
Nov 08
2022
|
Pratik Shah |
BUY
Grant, award, or other acquisition
|
Indirect |
10,156,204
+50.0%
|
-
|
|
Nov 08
2022
|
Justin Chakma Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
236,380
+50.0%
|
-
|
|
Aug 05
2022
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
78,740
+23.65%
|
$78,740
$1.27 P/Share
|
|
May 02
2022
|
Russ Hawkinson Sr. Vice President of Finance |
BUY
Grant, award, or other acquisition
|
Direct |
28,335
+43.2%
|
-
|
|
May 02
2022
|
Naomi Hunder Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,177
+44.24%
|
-
|
|
May 02
2022
|
Valerie Odegard President and CSO |
BUY
Grant, award, or other acquisition
|
Direct |
45,233
+42.32%
|
-
|
|
May 02
2022
|
Jonathan Piazza Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,691
+38.69%
|
-
|
|
May 02
2022
|
Laura Shawver |
BUY
Grant, award, or other acquisition
|
Direct |
68,107
+27.96%
|
-
|
|
Feb 01
2022
|
Valerie Odegard President and CSO |
BUY
Grant, award, or other acquisition
|
Direct |
16,406
+50.0%
|
-
|
|
Feb 01
2022
|
Laura Shawver |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+20.39%
|
-
|
|
Feb 01
2022
|
Naomi Hunder Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+50.0%
|
-
|
|
Feb 01
2022
|
Jonathan Piazza Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+30.58%
|
-
|
|
Feb 01
2022
|
Russ Hawkinson Sr. Vice President of Finance |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+45.58%
|
-
|
|
Dec 13
2021
|
Jonathan D Root Director |
SELL
Other acquisition or disposition
|
Indirect |
2,174,179
-100.0%
|
-
|
|
Nov 15
2021
|
Jonathan D Root Director |
BUY
Open market or private purchase
|
Indirect |
2,014
+46.0%
|
$16,112
$8.85 P/Share
|
|
Mar 03
2021
|
Jonathan D Root Director |
BUY
Open market or private purchase
|
Indirect |
350
+50.0%
|
$18,200
$52.07 P/Share
|
|
Dec 08
2020
|
Alexandria Venture Investments, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
699,412
+50.0%
|
-
|
|
Dec 08
2020
|
Peter A. Thompson Director |
BUY
Open market or private purchase
|
Indirect |
1,190,477
+40.97%
|
$25,000,017
$21.0 P/Share
|
|
Dec 08
2020
|
Peter A. Thompson Director |
BUY
Conversion of derivative security
|
Indirect |
7,011,765
+28.91%
|
-
|
|
Dec 08
2020
|
Jonathan D Root Director |
BUY
Conversion of derivative security
|
Indirect |
2,174,179
+31.13%
|
-
|
|
Dec 08
2020
|
Jonathan D Root Director |
BUY
Open market or private purchase
|
Direct |
95,238
+50.0%
|
$1,999,998
$21.0 P/Share
|
|
Dec 08
2020
|
Thilo Schroeder Director |
BUY
Conversion of derivative security
|
Indirect |
1,671,933
+31.92%
|
-
|